BioSight
Companies
Amylyx Pharmaceuticals, Inc. logo

AMLX

NASDAQCAMBRIDGE, MA
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals develops small-molecule drugs for neurology and metabolic disorders, with its lead program being avexitide for post-bariatric hypoglycemia currently in Phase 3 testing, and another candidate AMX0035 in development for Wolfram syndrome. The company also has earlier-stage programs including AMX0114 in Phase 1 for ALS and preclinical work on AMX0318 for post-bariatric hypoglycemia. Amylyx is dependent on obtaining regulatory approvals and successfully commercializing these candidates to generate revenue.

Price history not yet available for AMLX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar